Despite its sharp rebound, the sector remains about 40% below its pandemic peak, leaving it as one of the few areas of the ...

A lector, a once-high-flying Bay Area biotech company that researches treatments for degenerative brain disorders like ...

Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands ...

In the past week or so, a gold and silver miner, a struggling offshore driller, and a biotech saw some huge insider buying.

Join us as we dissect Summit Therapeutics' potential in the biotech sector. Can their promising drug Ansuvimab overcome the ...

The bar for product differentiation and commercial viability has never been higher. Efficiency, external collaboration, and ...

BIB ETF is best suited for high-risk, active investors in the accumulation phase or retirees managing portfolios hands-on.

Leverage RWE strategically to build regulator-ready submissions.

The company’s technology, a modified herpes simplex virus used to deliver gene therapies, was given the FDA’s new designation ...

Shares of mid-cap oncology specialist Exelixis are worth about $39 each right now. The biotech generates steady revenue and ...

Laramie startups are turning University of Wyoming research into products like natural mouthwash and kidney stone supplements ...

On October 2, Novonesis opened the doors of its North American headquarters in Franklinton inviting over 300 high school ...